| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5317016 | SHIONOGI INC | Pyrrolidylthiocarbapenem derivative |
Jun, 2015
(8 years ago) | |
| US8247402 | SHIONOGI INC | Crystal form of pyrrolidylthiocarbapenem derivative |
Mar, 2021
(3 years ago) | |
Doribax is owned by Shionogi Inc.
Doribax contains Doripenem.
Doribax has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Doribax are:
- US5317016
- US8247402
Doribax was authorised for market use on 05 October, 2010.
Doribax is available in injectable;intravenous dosage forms.
Doribax can be used as method of treating bacterial infections.
Drug patent challenges can be filed against Doribax from 13 October, 2011.
The generics of Doribax are possible to be released after 30 March, 2021.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
Drugs and Companies using DORIPENEM ingredient
NCE-1 date: 13 October, 2011
Market Authorisation Date: 05 October, 2010
Treatment: Method of treating bacterial infections
Dosage: INJECTABLE;INTRAVENOUS
How can I launch a generic of DORIBAX before it's drug patent expiration?
More Information on Dosage
DORIBAX family patents
